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Synthetic strategies and biomedical applications
of I–III–VI ternary quantum dots
Wubshet Mekonnen Girma, a Mochamad Zakki Fahmi,b Adi Permadi,a
Mulu Alemayehu Abatea and Jia-Yaw Chang *a
Surface modified and bioconjugated quantum dots (QDs) are of central importance in biomedical
applications. In this regard, particularly I–III–VI QDs are of specific interest for biosensors, multimodal
imaging, chemotherapy and for phototherapy in theranostic applications. Surface modification allows
management of the physico-chemical properties, biocompatibility, and pharmacological properties. This
review is anticipated to provide an introduction to new researchers about I–III–VI type QDs relating
to their synthesis, optical properties, surface modification, bioconjugation, and their applications in bio-
sensors, biological imaging, drug delivery, photothermal therapy and photodynamic therapy. We also
highlight introducing magnetic metals and nanoparticles to these QDs for multimodal imaging applications
and have addressed toxicity related issues. Finally, we summarize the results obtained and give a short outlook
on future directions of I–III–VI based QDs for biomedical applications.
1. Introduction
Quantum dots (QDs) are semiconductor nanocrystals with size
dependent optical and electronic properties which are composed
of inorganic core materials with an organic outer layer of capping
ligands. Colloidal QDs are characterised by their structures and
band gap energies (less than 4 eV) between the valance band (VB)
and conduction band (CB). The electronic properties differ from
the bulk crystals since, as the size decreases, the band gap energy
shifts to higher energy (shorter wavelength). The development of
different synthesis methods and size dependant optical properties
in the quantum confinement region has tremendous impact on the
advancements of a wide range of applications including solar cells,
photocatalysis, biosensing, drug delivery, detection and bioimaging.
To become biologically applicable, QDs should be bio-
compatible and ideally absorb in the near infrared region (NIR).
Such small fluorescent nanocrystals have recently become a major
focus in biological and medical sciences which enable high
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sensitivity imaging of cells, tissues and biomolecules. Such QDs
are of pronounced interest for advanced studies in a variety of
applications such as light emitting diodes,1–5 light-harvesting
systems,6 lasers and sensors,7 and biomedical labelling.8–10
The most intensively studied QDs are the II–VI, III–V and
IV–VI binary semiconductors such as CdS, CdSe, CdTe, PbS and
PbSe and their alloys, and they have been manly studied in
the form of size- and shape-controlled NCs during the past
decade.11–13
In comparison to the binary QDs, ternary I–III–VI (I = Cu,
Ag; III = In, Sn, Ga, Al and VI = S, Se, Te etc.) chalcopyrite
compounds, are composed of less toxic elements (free from Cd,
Hg etc.), and are considered as promising candidates to develop
eco-friendly QDs.
Although many reviews have been published on the use of
QDs in biology and biomedical fields,14–21 in this perspective,
mainly we summarize the different kinds of I–III–VI QDs
(such as CuInS2 (CIS), CuInSe2 (CISe), AgInS2 (AIS), AgInSe2
(AISe)), which have been applied in biosensors, imaging, drug
delivery, photothermal therapy (PTT) and photodynamic therapy
(PDT). Most of the chosen reference papers in this review are
related to ternary QDs applied to biological applications.
Moreover, a few representative papers not related to biological
application are cited to show different synthesis approaches
and optical properties of I–III–VI QDs. We hope to add some
value to this review by revealing many practical aspects of
synthesis approach, tuning optical properties, surface function-
alization and uses as biosensors, in dual modal imaging,
drug delivery and light-activated therapy, that are not clearly
explained and discussed in the general literature. We begin by
discussing the quantum confinement effect, and then discuss
optical properties of ternary QDs and core/shell systems, doping
heteroatoms, different synthesis approaches, phase transfer
strategies, and then functionalization and bioconjugation.
Finally, the biological application of I–III–VI QDs, specifically
CIS, CISe, AIS and AISe QDs in biosensors, imaging, drug
delivery, PTT and PDT, with toxicity related issues are discussed.
Each section provides a brief historical outline, which is important
to understand the follow up discussion in most recent progresses
in the field. We will attempt to guide new researchers in terms of
the advantages and disadvantages of every method in terms of
physical and chemical parameters, the choice of synthetic routes
and phase transfer strategies which leads to biocompatible QDs
with high fluorescent intensity, to serve as excellent candidates for
a number of in vivo and in vitro studies.
2. Overview of I–III–VI QDs
2.1 Summary on the uses of I–III–VI QDs
Studies focusing on I–III–VI QDs are growing in number and
attracting researchers from different areas. (i) Diode laser
applications ranging from their physics of operation to device
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engineering. (ii) Synthetic studies exploring different chemical
compositions and spectroscopic aspects. (iii) Developing novel
devices for the conversion of solar to electrical energy. (iv) Their
applications in biosensing, imaging phototherapy and chemo-
therapy of interest to biologists and medical science. Such
research could lead to a great contribution towards potential
improvements of these semiconductor materials in the future.
Biological applications with highly fluorescent and photo-
stable QDs requires QDs with NIR emission, small size, water
solubility and nontoxicity. Ternary chalcopyrite QDs can
achieve these requirements and hence are good candidates
for such applications. Particle size and stoichiometric composi-
tions variations allow to tune the emission wavelength in the
window for biological applications from 600–900 nm.
2.2 Quantum confinement, optical properties, and core/shell
structure of I–III–VI QDs
QDs are constructed from semiconductor materials and their
optical properties are greatly affected by the interactions among
electrons, holes and surroundings. Absorption of photons in
QDs is observed when the energy difference of CB and VB is
lower than the energy of absorbance. At this time, VB electrons
are excited to the CB leaving a ‘hole’. The average physical
distance between conduction electrons and valence holes is
defined as the exciton Bohr radius (aB). Once the electron is
excited to CB, it falls back down across the band gap towards
the VB. At this time electromagnetic radiation energy is lost and
the corresponding wavelength is emitted. Increase in band gap
energy is related to size, composition and shape of quantum
confinement. This is due to quantum confinement and will
happen when the QDs is in the size range of the exciton Bohr
radius.22,23 Quantum confinement in QDs is defined in terms
of decreasing QDs size and widening the band gap. In the case
of QDs the energy between VB and CB is discrete due to
quantum effects, and the energy band gap increases as the
QDs size decreases, which affects the properties. There are two
major effects which varies the QDs size. First, the surface atom
ratio in the QDs which contribute to the free energy and is
accountable for changes in thermodynamic properties. Second,
intrinsic properties of QDs which are transformed by quantum
size effects: optical and electrical properties of QDs show strong
variations with size. The most interesting properties of QDs are
their tunable optical and electrical properties as a function of
particle size (Fig. 1).24 The intrinsic electron and hole carriers
lead to increased band gap energy and to the splitting of
continuous energy bands in the discrete energy levels in spatial
confinement. This absorption and emission properties of
QDs are particularly important for biological imaging and
therapy.25
Ternary I–III–VI materials display direct band gap in the
visible region with band gaps of 1.05 eV (CISe) and 1.5 eV
(CIS),5,26,27 1.87 eV (AIS) and 1.2 eV (AISe).28,29 Ternary I–III–VI
QDs also have a large optical absorption coefficient for CIS
(a4 105 cm1),30 and high photostability (excited state lifetime).8
In addition to this, these QDs have been reported to display high
quantum yield (QY),31–34 long luminescence decay time and a
large Stokes shift (wide energy separation between absorption and
emission maxima).8,35,36
Moreover, composition variation consequences of I–III–VI
QDs can directly tune the optical properties. The presence
of different atoms in their composition enables tuning of
the absorption spectra. Several reports show that the non-
stoichiometry of ternary I–III–VI QDs could be controlled by
the molar ratios of precursors.8,37,38 The tunable emission is a
important property of I–III–VI QDs which attracts significant
research in biomedical applications, since fluorescence is
widely used in cell, tissue and animal experiments.
Ternary I–III–VI QDs prepared as core QDs exhibit poor PL
QYs of less than 20% and are not stable to photon-irradiation.
Surface coating of the QDs with materials having a large band
gap is a suitable way to enhance the PL QY as well as the
stability. The surface-to-volume ratio of QDs is high due to their
small size, as a result surface defects on unsaturated bonds on
the surface provides non-radiative decay pathways for the
photocreated charge carriers. Efficient surface passivation is
required to eliminate surface defects, improve the fluorescence
QY and stability. Introducing Zn2+ or ZnS was found to lead to
optimizing of optical properties of semiconductor QDs. Deng
et al.39 showed that increasing Zn in the AISe system led to a
blue shift on PL emission, which improved QY up to 50%.
Separately, Deng also investigated optical properties of AISe
after hot injection with ZnS:40 QY of AISe QDs can reach to 40%
with emission tunable from 700 to 820 nm. The emission range
makes these QDs suitable for biological applications.
For example, we have shown the PL QY of AIS is dependent
on the ratio of the cations ([Ag] : [In]). The fluorescent emission
was strongly dependent on QDs size and as the ratio of [Ag] : [In]
increases the crystal growth is faster. When the concentration of
indium is increased this reduces nonradiative recombination.41
Furthermore, recently Jara et al.42 reported that copper defi-
cient CIS QDs shows two independent optical transition
absorptions, related to excitonic and Cu-related sub band gap
Fig. 1 (A) Size dependent fluorescence spectra of quantum dots and (B)
different relative particle sizes with diameters between 2.1–7.5 nm.
(Reproduced from ref. 24 with permission from the Royal Society of
Chemistry.)
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states, respectively (Fig. 2). Hence an in depth knowledge of
photo-physical mechanisms will aid in controlling properties of
I–III–VI QDs and result in improvement of photovoltaic, light
emitting and biological performances. The band gap of QDs
can be altered by lattice stress created from the lattice mis-
match between the core and shell systems.43 The shelling
material should possess a larger band gap than the core to
deliver effective charge carriers while the crystal structure and
the lattice parameters should be close to those of the core to
facilitate epitaxial-like growth on the shell. The band gaps and
lattice parameters of various semiconductors usually used in
shelling the core are listed in ref. 11. As illustrated in Fig. 3,
core/shell systems can be type-I, type-II and quasi-type-II by
reference to their band alignments valance and conduction
bands of their constituent materials. In type-I (e.g. CdSe/ZnS,
InP/ZnS, CIS/ZnS, AIS/ZnS) core/shell systems the CB of the core
is lower in energy than the shell whereas the VB of the core is
higher in energy than the shell. Consequently, both holes and
electrons are confined within the core. Coating of core materials
with wide band gap materials is usually employed to reduce
nonradiative recombination which enhances PL QY and the
chemical stability. For example, Li et al. improved the QY of
CIS materials from 5–10% to 86% by adding a CdS shell.31 In the
case of type-II QDs (Fig. 3C) one of the materials has both VB and
CB higher in energy than the other material. Unlike type-I QDs
one of either the electron or holes is mainly confined to the core
while the other is confined to the shell. In type I/II core/shell
structures CdS,44 CdSe,45 ZnTe46 and ZnS47,48 are used as shell
materials.
The growth of a ZnS shell layer around the surface of the
core enhances the PL QY of the QDs. Most researchers choose
ZnS as a shelling material due to its chemical properties. First,
it has wide band gap (3.7 eV)49 and smaller ionic radii which
forms good band alignment with I–III–VI QDs. Second, its zinc
blende structure allows elimination of surface trap states and
avoids leakage created charge carriers in ternary core QDs. Xie
et al.50 demonstrated one layer of ZnS over the CIS core
improved the PL QY to 30%. Jang et al.51 synthesized CIS core
and passivated it with two layers of ZnS shell, and the fluores-
cence QY was increased to 92%. The double layer shelling of
ZnS leads to a remarkable blue shift from 660 to 559 nm.
Speranskaya et al.52 recently synthesized a core CIS core with a
PL QY of 28% and after shelling with ZnS the PL QY value
reached 80% with a stoichiometric ratio of Cu : In showing high
photostability under UV illumination both in toluene and
aqueous solutions. Surface reconstruction with ZnS provides
good stability by decreasing the size of core, and leads to a shift
in the absorption and emission spectra (Fig. 4).53
2.3 Doping heteroatoms to I–III–VI QDs
Precise and purposeful insertion of atoms into QDs in the bulk
form is known as doping. Doped QDs can introduce multi-
channel imaging application by introducing multiple emission
peaks. For instance, zinc (Zn) doped CIS/ZnS QDs show a blue
shift and can be applied for tumour targeted bioimaging.54
Tang et al.55 synthesized Zn doped AIS and comparison with a
pure AIS QDs indicated the incorporation of Zn dopant leads to
increased structure stability and crystallinity. Doping is also
performed to introduce magnetic functionality to the QDs to
afford contrast agents in MRI and multimodal imaging. Typically
for these purposes paramagnetic metal ions can be doped to
introduce spin–lattice relaxation and spin–spin relaxation
dynamics of protons in nearby water molecules which extends
Fig. 2 (A) Different [Cu]:[In] CuxInS2 QDs absorption spectra, (B) emission spectra and (C) emission quantum yield. (Reproduced from ref. 42 with
permission from the American Chemical Society.)
Fig. 3 Schematic band alignments: (A) type-I, (B) quasi-type-II and (C)
type-II at the heterointerface between two semiconductors of core/shell
QDs.
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the array of physical properties of the host QDs. For example
Yang et al.56 doped Gd3+ into CIS/ZnS QDs for fluorescent
MR/in vivo imaging.
More fundamentally, doping can vary the electronic, optical
and magnetic properties, and can be used to produce n-type
and p-type QDs which could be applied for solar cell devices or
to fabricate highly conductive NCs. Most focus has been on
transition metal dopants such as Cu, Mn and Zn which can
serve to tune the properties of the host QDs. In this respect,
when paramagnetic dopants are introduced into the lattices of
ternary QDs, escape of ions into the surrounding medium is
suppressed. One should consider that several synthetic methods
critically influence the doping efficiency as well as the optical
properties of the host QDs. Moreover, doping to core QDs
requires consideration of the ‘‘hard and soft acids and bases’’
(HSAB) principle; for example when considering Mn2+ and
Zn2+, Mn2+ has a harder nature than Zn2+, hence there is a
difference in solubility products which reduces their corres-
ponding metal sulfide co-precipitation during synthesis of
ternary QDs. In this regard, doping of soft acids to the ternary
system may facilitate the incorporation into the lattice crystal
and reaction with the anion precursor rather than hard base
solvents present in the reaction media. Therefore during synthesis
of doped ternary QDs it is necessary to target the acid strength of
the dopant and choose appropriate ligands most specifically in
aqueous phase synthesis approaches.
3. Synthesis and modification
of I–III–VI QDs
Several researches on the synthesis of I–III–VI QDs and effective
routes to highly luminescent core/shell ternary QDs have been
reported.31,57–60 Fabrication of I–III–VI QDs are adapted from
the methods used in II–VI binary QDs from the literature.61–63
During synthesis of QDs, the reaction temperature and time,8,64
injection temperature in hot-injection methods,65 the reactivity
and the stoichiometric ratios of precursors, the solvent type
used, surfactant, and pH,66 etc. are important parameters to
adjust the size and composition. A number of metal salts and
sulfur precursors are used for the preparation of luminescent
I–III–VI QDs by thermolysis in hot organic solvents.35,64,67–69
Difficulties faced in the synthesis of ternary QDs arises from
the fact that the chemistry of I–III–VI QDs can be particularly
complex given the chemical properties of the two cations.
Cu+ and Ag+ are soft Lewis acids, whereas In3+ is a hard one;
consequently, there is a difference in their reactivity towards
sulfur compounds (soft Lewis bases). Unbalanced cationic
precursors will lead to the formation of copper sulfides or silver
sulfides and indium sulfides, rather than growth of ternary QDs.
Regulating the reactivity of Cu and In precursors at the same time
can be achieved by having more than one kind of capping ligands,
e.g., a thiol and a carboxylic acid, for controlling the reactivity
of Cu+ and In3+ cations, respectively.50,70 Also using one excess
stabilizer as a solvent and ligand, e.g., thiol,31,35,71 is another
alternative to reduce the cations forming side reaction products.
Another strategy to avoid the problem of different reactivities is
the use of single precursors containing both precursor cations,
which provides the same amount of Cu and In at once, which
promote the formation of CIS or CISe instead of metal
sulfides.67,72 In 2003 Castro et al.67 synthesized CIS and CISe
QDs through single precursors using (PPh3)2CuIn(SEt)4 and
(PPh3)2CuIn(SePh)4 respectively. Although the particle size of
CIS they synthesized is not small enough (larger than 8 nm) to
exhibit quantization effects, these precursors provided a route
to colloidal chalcopyrite QDs. In 2004 they modified the experi-
mental conditions and successfully synthesized CIS QDs smaller
than 4 nm size by increasing the reaction temperature.68 Ternary
QDs have enhanced significance as compared to binary QDs since
they have larger Stokes shifts, enhanced PL lifetime and size
tunable emissions and low toxicity. However, the PL QY is mostly
less than 10%, which is not sufficient for practical use.31,50,73
Based on these studies numerous efforts has been made to raise
the PL QY; for example, Uehara et al.37 enhanced the fluorescence
of CIS QDs by introducing crystal defects through a highly Cu
deficient composition from CIS. This enhanced fluorescence was
due to large number of donor or acceptor defects required for
‘‘donor–acceptor pair recombination (DAP)’’ of excited charge
carriers.35,74 Hamanaka et al.75 showed the decrease in PL QY in
CIS QDs is associated with deep surface traps rather than DAP.
These opens a way for researchers to construct efficient
approaches for modifying the surface of ternary core QDs.
3.1 Nucleation and growth
The synthesis process of core/shell systems involves two steps,
initial core QDs synthesis and subsequent shell growth. During
growth of shells a few monolayers of a material is deposited on
the surface of the core.
Basically according to the model of Lamer,106 with colloidal
systems, QDs are synthesized via a three-stage process (Fig. 5).
In stage one, the precursor compounds are rapidly mixed with a
mixture of solvents and organic ligands. The monomer con-
centration increases until critical supersaturation is reached.
Fig. 4 (A) Absorption spectra and (B) PL spectra of CIS/ZnS QDs with
different Cu/In ratios in the cores; (C) corresponding digital pictures of
CIS/ZnS QDs under UV-light irradiation. (Reproduced from ref. 53 with
permission from the American Chemical Society.)
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At this point, seed particles precipitate spontaneously from
solution (nucleation, stage 2). This is followed by a period in
which the newly formed seeds capture dissolved atoms or
molecules from solution, and grow to form the desired QDs
until complete depletion of monomers (growth, stage 3).
However, further growth of the formed QDs may occur due to
Ostwald ripening, where large nanoparticles compete with
small nuclei during formation. Ostwald ripening is the mechanism
of growth by which smaller particles dissolve and molecular
species are released for the formation of larger particles. This often
leads to the dissolution of smaller particles at the expense of
further growth of the larger ones. This process typically results to
the formation of polydisperse samples. One can note that during
the growth of the QDs there is formation of new nuclei, which may
cause a spreading of the distribution of sizes of the colloidal QDs.
During synthesis of colloidal QDs the temperature plays
a key role. First, an adequate amount of thermal energy is
required for atoms to rearrange in ordered structures for the
formation of crystals. Generally, lower reaction temperatures
are required for synthesis of nanomaterials; consequently, their
melting temperature depends on the thermodynamic size effects.
Capping ligands also have to be considered, since they can also
form complexes with the precursors used rather than binding to
QDs. The capping ligands affinity to the surface and thermal
stability associated with these complexes is also strongly depen-
dent on the reaction temperature. A lower reaction temperature
leads to stable complexes, lower reactivity of precursors (decreased
diffusion rate) and strong binding of the ligand to surface of QDs.
Nevertheless, working at higher temperature could lead to less
control of size and shape or aggregated system. Consequently, use
of a suitable temperature is extremely important for control of the
size and shape of QDs.
The type of capping ligands is another key parameter to
adjust the synthesis of QDs. Weak capping ligands cannot
prevent aggregation of the forming particles while strong
coordinating ligands may hinder the nucleation and/or growth
of QDs.
Generally, for the synthesis of semiconductor QDs there
are several methods and some of them are discussed below
accordingly in terms of the solvent, reaction temperature,
quality of products etc. Variation of metal salts and sulfur
sources along with their synthesis methods, reaction tempera-
ture and applications are summarized in (Table 1) for CIS and
CISe and (Table 2) for AIS and AISe QDs.
3.2 Hot injection method
The developments of colloidal chemistry enable low cost pro-
duction of high quality QDs through a wet chemistry process of
QD colloidal solutions which has attracted great attention.
In this method, precursors and surfactants react in a high
temperature reaction in the presence of stabilizers. Surfactants
have a polar head group and one or more hydrophobic hydro-
carbon chains. A mixture of coordinating solvents and surfac-
tants are heated in a reactor under argon or nitrogen flow, and
precursors are quickly injected in the hot solution which leads
to supersaturation. The aggregation of precursors generates
reactive species which induces nucleation followed by the
growth of these nuclei. The size distribution of QDs is a kinetic
process, and can be controlled by fast or slow injection, driven
by initial supersaturation. Fast injection delivers a narrow size
distribution of QDs. In this approach, formation of a new phase
during precipitation involves two distinct stages; the formation
of initial nuclei (crystallization) and growth. To control the
growth of QDs, ligands and concentration of reactants contri-
bute to adjust the surface energy and chemical potential of the
reaction, respectively. The hot injection method produces
monodispersed QDs. Organic amines and phosphines are the
most widely utilized ligands in this approach. A real break-
through come when Murray et al.61 investigated the reaction
mechanism for the synthesis of monodisperse CdS, CdSe and
CdTe QDs by using a mixture of tri-n-octylphosphine (TOP) and
trioctylphosphine oxide (TOPO) as high boiling point solvent/
ligand. In continuation of this approach researchers success-
fully implemented this route to synthesize other QDs, such as
CdSe and CdTe,61 ZnSe,107,108 PbS,109 PbSe,110,111 PbTe,112,113
CIS,114–116 CISe,98 etc. Park et al.117 synthesized CIS QDs having
a fluorescent QY of 8% and emission peak at 645 nm via the hot
injection approach. They added a ZnS shell by using zinc
acetate for Zn source and it showed a blue shift by decreasing
the size of core (Fig. 6). Often, Zn salts or ZnS are used as
combining agents to the improve optical properties of the QDs.
Allen et al.79 recently demonstrated CISe QDs synthesis; using
bis(trimethylsilyl)selenide as a chalcogenide precursor with
good size control, but only the ordered vacancy chalcopyrite
compounds were formed using these approach. In 2011 Park
et al.118 demonstrated one-pot synthesis of CISe core having
emission peaks in the window of biomedical application. Latter
they modified the band gap by using a ZnS passivation layer,
Fig. 5 Schematic representation of nucleation and growth of nanocrystals
and illustration of the steps in synthesis of colloidal QDs.
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with the CISe/ZnS core/shell system showing a blue shift for
bioimaging application. Post synthetic treatment of I–III–VI
QDs improve the optical properties and surface states which
imparts good stability. Yarema et al.94 synthesized luminescent
CISe by using silylamide and controlled the size of the QDs in
between 3 and 5 nm by tuning the growth time, temperature,
and amount of silylamide. The QDs growth temperature and
time have influence on the size of particle which in turn alters
the absorption and emissions of QDs. Modification with ZnS
(via ZnS coating, Zn diffusion and alloying with ZnS) to form
AIS–ZnS (ZAIS) nanostructures is often done to enhance the PL
properties of AIS. For instance, Xiang et al.119 have successfully
prepared AIS and AZIS QDs with various stoichiometries.
By varying the Ag to Zn ratio, it is observed that addition of
Zn to the crystal system effects the absorption peaks that tend
to blue-shift (739 to 632 nm) and their emission wavelengths
move to a higher energy accordingly, showing a quite tunable
emission from red to green. Noteworthy, Zn on AIS can enhance
QY up to 62% and be finely adjusted in the whole visible
spectrum. Torimoto et al.120 also proposed a strategy for
optimizing QY of AIS. In the study, AIS QDs which were
prepared via a pyrolysis process were further coated with ZnS
separately giving the highest quantum yield of ca. 80%. In our
previous work, we tried to develop ZnS coating onto the AIS
synthesis process via one-pot hot injection process.121 By this
simplified synthesis step, QY can be increased up to ca. 70%










(%) Material Application Ref.
Cu(S2COEt), In(S2COEt)3, EG Heating up 196 642 — CIS — 76
[P(i-But)3]2CuIn(SEt)4 or (PPh3)2CuIn(SEt)4, DOP Microwave 140–170 603.5–656.5 — CIS — 77
Cu(ac)2H2O, InCl34H2O, CS2 Solvothermal 200 835 — CIS — 78
CuAc, In(OAc)3, DDT, ODE Solvothermal 240 600–750 — CIS — 35
CuI, InCl3, (Me3Si)2Se, OA, TOP Hot injection 200–280 640–975 25 CIS — 79
Cu(S2CNEt2)2, In(S2CNEt2)3, OA, ODE Hot injection 200 — — CIS Solar cell 64
CuI, InI3, DDT, OA, ODE Heating up 160–240 702 5 CIS — 37
CuI, In(OAc)3, ZnSt2, DDT, ODE Heating up 200–270 650–830 60 CIS/ZnS In vivo imaging 8
Cu(dedc)2, In(dedc)3, Zn(dedc)2, DDT Hot injection 120–200 — — CIS/ZnS Photovoltaic and
photocatalytic
80
CuI, In(OAc)3, DDT, ODE Heating up 120–200 700–850 CIS Light emitting
and solar cell
70
CuCl, InCl3, sulfur, OA Solvothermal 110–170 — — CIS Solar cell 81
CuI, In(OAc)3, Zn(OAC), DDT, ODE Solvothermal 180 647–664 65 CIS/ZnS — 82
CuI, In(OAc)3, DDT, ZnSt2, MA, ODE Heating up 110–250 645 65 CIS/ZnS — 83
CuI, In(OAc)3, ZnSt2, DDT Heating up 100–230 630–780 86 CIS — 84
CuI, In(OAc)3, DDT, ODE Heating up 120–230 683 — CIS — 85
CuCl22H2O, InCl34H2O, CS(NH2)2, MPA Hydrothermal 150 660 3.3 CIS Biomedical imaging 66
Cu(NO3)2, In(OAc)3, sulfur, Zn(OAC)2OA Hot injection 90–170 650–800 30 CIS/ZnS In vivo imaging 86
CuI, In(OAc)3, DDT Solvothermal 180 654–659 CIS White LED 5
InCl3, CuCl2, Na2S, Zn(OAc)2 Hydrothermal 100 532–655 CIS/ZnS 87
CuCl22H2O, InCl44H2O, Zn(OAC)2, DDT, ODE Heating up 100–250 450–559 80 CIS/ZnS/ZnS White LED 88
Cu(NO3)23H2O, In(NO3)25H2O, Na2S9H2O, GSH Hydrothermal 100 654–800 — CIS In vivo imaging 89
CuCl, InCl3, Se powder, DPP, OA Hot injection 100–240 735–800 CISe Solar cells 90
CuI, In(OAc)3, Se powder, DDT, ODE, TBP Hot injection 200 600–850 26 CISe//ZnS LEDs, biolabeling 91
CuI, InI3, (TMS)2Se, TOPO, HDA, (TMS)2S,
diethyl zinc, DDT
Hot injection 270, 130 700–900 60 CISe/ZnS Biomedical imaging 92
CuI, InCl3, Se powder, TOP, (Zn(CH3COO)2),
HDA, OLA
Hot injection 200–280 619 16 CISe/ZnSe Solar cells and LEDs 93
CuCl, InCl3, TOPSe, (LiN(SiMe3)2), ZnEt2, TOPS Hot injection 285, 320 700–1200 60 CISe/ZnSe Bioimaging, biolabeling,
and lighting applications
94
Cu(acac)2, In(acac)3, Se powder, TBP, DDT,
S source, ODE, zinc(II) oleate
Hot injection 220 750 40 CISexS2x/ZnS Bioimaging 95
CuCl, InCl3, seleneourea, ODE, TOP, DDT, Zn(OA)2 Heating up 140–250 700–1040 50 CISe/ZnS Biomedical imaging 96
CuI, (In(OAc)3), Se powder, DDT, ODE, OLA Hot injection 130, 180,
200
709 CISe/ZnS Bioimaging 97
CuI, InI3, (Me3Si)2Se, TOP, OA Hot injection 280, 210 650–975 25 CISe Bioimaging 98
CuI, InCl3, Se powder, TOP, ODE Heating up 320 838–918 25 CISe Solar cells 99
Cu(acac)2, In(acac)3, Se powder, TOP ODE, OA Solvothermal 170, 120 CISe Solar cells 100
CuCl, InCl34H2O, Se powder, OLA Solvothermal 220, 70 15 CISe Photo catalyst 101
Cu powder, In powder, Se powder, DI water Hydrothermal 180–220 863 CISe Photovoltaic devices 102
CuCl2, In(OH)3, Se powder, Gelatin Heating up 120, 80 612–686 23.3 CISe/ZnS LED 103
CI, InI3, Se powder, OLA Hot injection 80–270 73 CISe Photovoltaic device 104
CuI, (In(OAc)3), Se powder, (Zn(OAc)2),
S powder, OLA
Hot injection 180 810 CISe/ZnS Photovoltaic device 105
EG: ethylene glycol, DOP: dioctyl phthalate, OA: oleic acid, OLA: oleylamine, TOP: trioctylphosphine, DDT: dodecanethiol, ODE: 1-octadecene, MA:
myristic acid, MPA: mercaptopropionic acid, GSH: glutathione, DPP: diphenylphosphine, TBP: tributylphosphine, (TMS)2Se:
bis(trimethylsilyl)selenide, TOPO: trioctylphosphine oxide, HDA: hexadecylamine.
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with a slight blue shift from 570 to 520 nm. Increasing QY after
ZnS coating is considered to be due to the role of ZnS as a
passivating layer which could remove non-radiative recombina-
tion sites on surface of AIS.









(%) Material Application Ref.
AgNO3, InCl34H2O, DDT Hot injection 170 639–732 at
specific Ag/In
62 AIS LED 119
AgNO3, In(NO3)3xH2O,
diethyldithiocarbamate trihydrate
Hydrothermal 60 480–700 AIS Cellular imaging
and siRNA delivery
145
AgNO3, In(NO3)3, NaS2 Hydrothermal 100 595 20 AIS Bioimaging 146, 147
[Ag(HSal)], InCl3, sulfur Microwave 350 653 14 AIS Ion detection,
bioimaging, solar cell
150–152
AgNO3, In(Ac)3, sulfur Hot injection 200 650–820 AIS Bioimaging 153, 154
AgAc, In(Ac)3, DDT Hot injection 270, 210 670 28 AIS Bioimaging 131, 136, 137, 155
AgNO3, InCl34H2O,
N,N-diethyldithiocarbamate trihydrate
Heating up 180 580–750 70 AIS Solar cell 120, 125, 156, 157
AgNO3, In(Ac)3, sulfur Hot injection 130 644 AIS LED 132
AgNO3, In(stearate), DDT Hot injection 180 580 22 AIS Bioimaging 121, 135
AgNO3, In(Ac)3, DDT Hot injection 175, 115 675 50 AIS Solar cell 114, 130
AgNO3, In(Ac)3, L-cysteine Hydrothermal 110 560 26 AIS Bioimaging 148
AgI, InI3, (Me3Si)2Se Hot injection 280 650 15 AISe 98
AgNO3, In(Ac)3, Se powder Hot injection 175 700–820 40 AISe Bioimaging 40
AgAc, In(Ac)3, selenourea Heating up 250 AISe Solar cell 126
AgNO3, In(Ac)3, Se powder Hydrothermal 90 625–940 31 AISe Bioimaging 158, 159
Ag2O, In(Ac)3, Se powder Hot injection 230 800–1300 21 AISe Bioimaging 39, 160
AgNO3, In(NO3)3, NaHSe Hydrothermal 100 504–585 15 AISe Bioimaging, LED,
optical coding
149, 161
Fig. 6 The emission (a–c) and absorption (d–f) spectra of different size CIS core QDs before and after formation of a ZnS shell. (g–i) Photos of the
corresponding core and core/shell under UV-irradiation. (Reproduced from ref. 117 with the permission from the Royal Society of Chemistry.)
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3.3 Non-injection (heating up) approach
In this protocol the reaction solution is prepared at low tempera-
ture and subsequently heated to generate the crystallization
process which leads to the QDs growth at elevated temperature.
The heating up method usually consists of a high temperature
decomposition of metal salts in the presence of surfactant and
high boiling point solvents. The crystallization process is used
to control the size distribution of the QDs and the reaction
temperature depends on the reactivity of the precursors. In 2004
Cao et al.122 synthesized CdS by using nucleation imitator
compounds (tetraethylthiuram disulfides and 2,20-dithiobisbenzo-
thiazole) to isolate the nucleation and growth steps in homoge-
neous reaction systems. Recently in 2014 Xia et al.123 synthesized
CIS via one step by adjusting kinetic variables and coordinating
molecules, such as reaction temperature, time (Fig. 7), stoichio-
metric ratio of precursors and stabilizing ligands. Unlike the
hot injection approach, the system consists simultaneously of
two different reactants before the reaction starts at a certain
temperature. In this approach, instantaneous supersaturation
is induced and crystallization-rate is less controllable. Due to
characteristic limitations of the injection method various
research groups have synthesized CIS by using the simple
heating up approach.8,35,37,70,124 As an example, Li et al.31
demonstrated the influence of increased temperature on the
growth of CIS QDs as indicated by an emission peak shift from
630 to 780 nm indicating increasing particle size. Increase in
reaction temperature facilitates the growth of particles so
introducing a degree of control. Desired sizes can be obtained
after quenching the reaction by putting the flask in a
water bath.
Dai et al. and Kameyama et al. was reported utilization of a
non-injection pyrolysis method for the synthesis of AIS and
AISe QDs.125,126 However, even prepared with precisely stoichio-
metric composition, there are difficulties in obtaining QDs
with single crystal structures. For instance, synthesis of AIS
proposed by Dai et al.125 leads to AIS QDs with tetragonal and
orthorhombic crystal forms, additionally, cubic AgIn5S8 is also
obtained (Fig. 8). The heating up method is particularly advan-
tageous for large scale synthesis of QDs as large amounts of
precursors in a large volume reactor can be used.
3.4 Solvothermal approach
Solvothermal synthesis is a method similar to hydrothermal
synthesis, but involves organic solvents instead of water.
Compared to other methods, solvothermal synthesis has several
advantages. First, solvothermal conditions permit rapid convec-
tion in solution. The comparably mild environment offers con-
ditions to form crystals with few lattice defects and allows for the
precise control over the size, shape distribution, and crystallinity
of nanoparticles.127 Second, low boiling point of the used
organic solvent can provide a higher reaction pressure when
conducted at higher temperatures, which will contribute to the
process of crystallization. Third, because of the mild temperature,
special structural features of precursors can be transferred to the
products so that the morphology of products can be controlled.
Solvents can also provide functional groups, which can further
react with the precursors or the products to synthesize novel
materials.128,129 Finally, for some reaction systems such as those
including toxic starting materials, solvothermal synthesis can
reduce the release of harmful vapour during the reaction. Further
the trend towards to greener technologies promotes this approach,
since it reduces consumption of energy and use of expensive
solvents. 1-Dodecane (ODE) is widely used in preparing both
ternary I–III–VI QDs combined with several ligands such as oleic
acid (OA),114,130,131 1-hexadecylamine (HDA),132 oleylamine
(OAM),133–135 1-dodecanethiol (DDT),39,40,130,136 and TOP.98,114,131
The application of DDT in preparing CIS and AIS has advantages
in terms of potency as a ligand but also as a sulfur precursor for
the QDs.121,137
Nam et al.138 synthesized CIS QDs solvothermally at a fixed
temperature of 180 1C for different reaction times and the best
result was at 5 h 40 min with a QY 8.8%. Solvothermally
synthesized QDs are mostly hydrophobic in nature, hence for
biological application and to improve the stability they have be
transformed to a hydrophilic phase.
3.5 Hydrothermal approach
The principles of green chemistry attract many scientists
involved in the synthesis of nanomaterials. For example, the
use of non-toxic reagents and solvents, increasing the product
yield, simplicity of the purification steps, minimizing the
Fig. 7 (a) The absorption and (b) emission of CIS at different synthesis times for a given temperature. (Reproduced from ref. 123 with the permission
from the Royal Society of Chemistry.)
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amount of organic solvents will reduce the cost of synthesis and
result in reduced environmental impact.
Among the various methods of synthesis of colloidal QDs,
aqueous synthesis employs environmentally friendly solvent,
biocompatibility and it is not restricted to an inert atmosphere.
The general synthetic approach mostly involves chemical reaction
between metal precursors and surface ligands. As a metal
precursor metal halides or nitrates, which are directly soluble
in water, and as a sulfur source, Na2S
53,139 and sulfourea
(CS(NH2)2),
140 are mostly used. It has some distinct advantages
in addition to the features of the solvothermal process. Key
features of the hydrothermal approach are facile preparation,
direct water-solubility, good reproducibility, low cost, and
improved biocompatibility.141,142 Rogach et al.143 demonstrated
the aqueous phase synthesis approach of CdTe QDs for the
first time.
One-pot direct aqueous synthesis of water-soluble CIS-based
QDs can be highly effective. Various hydrophilic short chain
thiols (Fig. 9) are usually utilized as the ligands, such as reduced
glutathione (GSH), poly acrylic acid (PAA), and thioglycolic acid
(TGA) etc., to prepare water-soluble CIS and CISe-based QDs. The
first study on applying a hydrothermal approach for the synthesis
of AIS was proposed by Luo et al.,144 where they synthesized AIS
QDs capped with GSH directly in water for photocatalytic
application, though with low QY (15%). However, to be effec-
tively applied in both clinical and biological applications, it is
necessary to obtain high QY of QDs that are both water-
dispersible and biocompatible. Based on this, several studies
use a hydrothermal synthesis approach as a direct route to
obtain bio-applicable QDs. Besides GSH,27,38 some hydrophilic




NaHSe,35,36 have been used to produce water soluble ternary
system QDs which are used for biological applications. The
hydrothermal method is also very flexible to alloy other elements
into the AIS system resulting in improved QDs. Doping Zn2+ on to
AIS system (AgIn5S8 QDs) was proposed by Song et al.
148 resulting
in enhancement of QY of QDs up to 35%. This study utilized
L-cysteine as a hydrophilic ligand and sulfur source. Separately,
doping Ag+ in ZISe QDs system also investigated using a hydro-
thermal synthesis process.35,149
3.6 Microwave irradiation approach
Synthesis of colloidal QDs using microwave heating is recently
found to be a better approach as compared to other methods
due to its numerous advantages. In microwave assisted reactions
Fig. 8 (i) XRD patterns of AIS nanoparticles prepared from pyrolysis synthesis process. (ii) (a) UV spectra, (b) PL spectra and (c) photograph of AIS.
(Reproduced from ref. 125 with the permission from the Royal Society of Chemistry.)
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the process is conducted at the boiling point of the solvent, at
normal pressure; small particle size QDs can be prepared,162 only
short reaction time is required, purity of the product is good, and
reproducibility and product yield is better.163
In motivation to design faster, cleaner, and economically
more viable synthesis methods, many studies use microwave
heating. Utilization of microwave heating in conducting
chemical reactions has been adopted due to its numerous
effective applications in polymer synthesis,164 material sciences,165
nanotechnology162 and biochemical processes.166 In general, some-
times extreme temperature and the rapid heating in microwave
chemistry leads to faster processes. Thermodynamic and kinetic
barriers of the reaction are important factors for the growth of QDs.
In ordinary thermolysis reaction, conduction of black body radiation
is used to drive the reaction, using the reaction vessel for transfer
of energy. This can cause sharp thermal gradients in reaction
conditions leading to non-uniform nucleation and particle growth.
Xiong et al.152 synthesized AIS using a microwave radiation
approach and further coated it with ZnS. Even using a two-step
synthesis process, each process was rapid and the product
showed fluorescence, low toxicity and long PL lifetimes suitable
for biodetection and bioimaging. The microwave synthesis
technique was also developed by Mousavi-Kamazani et al.150
to produce composite Ag2S–AIS system QDs. This study showed
a clear relation between microwave power and irradiation time
on the obtained nanoparticles, where higher microwave power
or longer irradiation time led to increased particle size. However,
most synthesis processes with the microwave approach resulted
in low QY value and this problem needs to be solved.
More recently our group, synthesized Gd-doped CIS/ZnS
using a facile microwave assisted approach (Fig. 10) which
results in enhanced photostability applicable for both fluorescence
and magnetic resonance clinical applications.167 We summarize
the differences of the above mentioned synthesis protocols
according to their advantages and disadvantages in Table 3.
3.7 Phase transfer strategies and bioconjugation
QDs are mostly synthesized in nonpolar organic solvents. Since
their surface is hydrophobic (aliphatic ligands such as alkyl
phosphine oxides, aliphatic amines, alkyl phosphines, aliphatic
carboxylic acids), we require surface coating to disperse the
QDs in aqueous solution. Solubilization in aqueous systems
Fig. 9 Chemical structure of different possible capping ligands involved in aqueous synthesis of I–III–VI QDs.
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and surface functionalization are important for many bio-
logical applications, but these processes require sophisticated
surface chemistry, which is often a significant challenge.
Further, QDs require ligands that modify the surface defect
sites, leading to bright, photostable QDs. As shown in sche-
matic representations in Fig. 11, various strategies have been
developed to change the hydrophobic surfaces of QDs, to
hydrophilic surfaces.7,168 These strategies generally can be
grouped in two types. The first protocol is ligand exchange of
the original surface ligands by hydrophilic molecules.24 The
most widely used ligands are monothiolated ligands like GSH
and 3-mercaptopropionic acid (MPA),169,170 mercaptoacetic
acid,171 bidentate thiols (dihydrolipoic acid derivatives),172 alkyl
thiol terminated DNA,173 thioalkylated oligo ethyleneglycols.174
In this strategy, the molecules stabilizing QDs in the original first
phase are changed by new stronger binding ligands and allow the
transfer to the aqueous phase which also provides colloidal
stability. The advantage of this method is an only small increase
in the hydrodynamic radius of the QDs. This is of strong interest
in QD based fluorescence resonance energy transfer (FRET)
investigation175,176 and for some biological applications which
require high diffusional motilities.177,178 Though there are limita-
tions of this method, the stability of the thin surface ligand is
often affected by local conditions, such as concentration, pH, and
temperature.172 Such conditions may prevent dispersion in the
cytosol of cells. Recently, some new approaches by using similar
thiol-containing molecules as L-cysteine,179 poly(ethylene glycols)-
terminated dihydrolipoic acid (PEG-DHLA)180 have been devel-
oped for solubilization and functionalization of QDs and achieved
significant in vitro and in vivo stability.181–184 PEG-DHLA ligand
has advantage to provide QDs small hydrodynamic size, low non-
specific binding and high QY and shows good solubility over a
wide range of pH. Li et al.8 synthesized CIS/ZnS core/shell QDs
initially capped with DDT surface ligand, transferred to the
aqueous phase using surface ligand exchange with DHLA, and
the functionalized QDs were used for in vivo imaging. Subrama-
niam et al.185 have utilized MPA as a new binding ligand for
dodecylamine-capped ZnS–AIS followed by polymer coating to
functionalize and load siRNA. The resulting water soluble QDs
has been proven to show low toxicity and to be readily applied for
brain tumor staining and delivery of siRNA in vitro. However, a
considerable issue in phase transfer via ligand exchange is the
stability and the optical properties, in particular of QD fluores-
cence. In the aqueous phase, both the QDs surface and probably
the thiol groups of the ligands are susceptible to oxidation. In this
situation, the fluorescence QY is reduced and desorption of the
capping ligands can eventually lead to aggregation.
The second strategy is based on encapsulation into a layer of
amphiphilic diblock186 or triblock copolymers,187 phospholipid
micelles,154,188,189 silica shells,190 dendrimers,191 or amphiphi-
lic polysaccharides,192 polymer shells,185,193–195 oligomeric
phosphine coating,196 or by phytochelatin-peptides coating,197
or histidine-rich proteins,198 or fatty acids.199 This strategy was
developed to overcome decreased optical properties of QDs as a
limitation of the ligand exchange method. Formation of a
multilayer ligand allows transfer from an organic phase to
Fig. 10 Schematic of the formation of the Gd:CIS core and Gd:CIS/ZnS
core/shell QDs using a microwave irradiation synthesis approach. (Reproduced
from ref. 167 with permission from the Royal Society of Chemistry.)
Table 3 Summary of features of different selected synthetic methods of ternary I–III–VI QDs
Synthesis
method Advantage Disadvantage
Hot-injection Size control, higher quantum yield High temperature, difficult for large scale production, use
of organic solvents, use of inert atmosphere, reproducibility,
reagent mixing time, cooling time
Heating Easy large scale production, reproducibility High temperature, use of organic solvents
Solvothermal Size control, shape distribution, crystallinity of NCs,
morphology, and reduce the release of harmful vapors
Use of organic solvents
Hydrothermal Nontoxic solvent, cost effective, biocompatible, direct water
solubility, reproducibility
Poor size control, lower PL QY
Microwave
irradiation
Rapid, highly pure product, environmentally friendliness, low
energy consumption, easy control of pressure and temperature
profile, reproducibility, initiate rapid homogeneous nucleation,
reduced crystallization time, narrow size distribution
Lower PL QY
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water phase. In this strategy, the molecules that act as phase-
transfer agents have amphiphilic nature comprising of a hydro-
phobic and a hydrophilic part. For instance, a study on phase
transfer strategy of CIS/ZnS and AIS/ZnS was conducted by
Liu et al.86 via micelle-encapsulated QD formulation. In the
process, the Pluronics F127 block copolymer was used as
the micelle precursor, which drives organic soluble QDs into
the water phase with good optical and colloidal stability for more
than 2–3 weeks. Previously, Tang et al.200 also proposed Pluronics
F127 as transferring polymer of AIS/ZnS and applied the trans-
ferred QDs as a staining agent on tumor cells. It is claimed that by
this phase transferring process, the resulting QDs still maintain
their original optical properties and were easily concentrated by
slight heating to obtain desired concentrations. It was well-known
that application of synthetic polymers or macromolecule materials
in biological applications is favorable based on their durability and
simplicity in preparation. However, in terms of safety and ease for
further modification, natural polymers or biomacromolecules are
the better choice. These materials offer the improvement of having
the intrinsic property of environmental responsiveness as well as
non-toxicity, even at high concentrations. Based on this considera-
tion, formation of micelles was also proposed by Deng et al.201 for
transferring hydrophobic Zn doped AISe. The micelle was prepared
via amphiphilic modification of chitosan by tagging with succinic
anhydride. Interestingly, in this study the micelle was firstly
attributed with RGD as tumor targeting agent before QD insertion
(Fig. 12). In this way, the hydrophobic QDs can be effectively
loaded and simultaneously transferred to water, in which the
crystal structure, shape, and optical and electronic properties of
the initial QDs were retained. Foda et al.202 synthesized CIS/ZnS
QDs in organic solvents at elevated temperature and used lipo-
philic silane encapsulation to make them hydrophilic for cancer
cell imaging. Such encapsulated QDs have advantages, high PL
efficiency and improved stability, but the thick overcoating pro-
duces large hydrodynamic diameters in the range of 20–30 nm for
a 4–6 nm core/shell QD. This is limiting for biological application
since they are much larger than the cellular receptors. However,
the size could be reduced to the range of 17–25 nm by controlling
the silica shell size and led to good biofunctionalization in cell
imaging. As an alternative, Sheng et al.203 proposed a phase
transfer strategy of organic soluble Zn doped AIS via a template
coating route with formatting silica layer on the QDs surface. The
silica as shell of QDs can maintain the QDs from environmental
damage such as oxidation and dissolution.
In our previous work, we also proposed a phase transferring
strategy of organic soluble AIS/ZnS by utilizing a protein macro-
molecule, namely bovine serum albumin (BSA) with sonication
treatment.204 In this work, the BSA can accommodate organic
soluble QDs by physical interaction with the ‘‘hydrophobic
pocket’’ on the part of BSA covering the hydrophilic part. This
situation allows the QDs to be stabilized in water. BSA is a
versatile material with the ability to bind to many molecules
and we showed folic acid and doxorubicin can interact with a
BSA/QD composite via covalent and non-covalent interaction,
respectively (Fig. 13). Besides large molecules, phase transfer of
organic soluble AIS QDs was also performed with small molecules.
We proposed a smart strategy for facile phase transfer of QDs by
utilizing small amphiphilic molecules, by use of fatty acid, OAM,
DDT and dodecanediol.137 On ultrasonication treatment, the
hydrocarbon part of the amphiphilic molecules can form van
der Waals interactions with the hydrocarbon part of QDs, with a
resulting transfer process. Using this approach, the transferred
QDs still maintain their size and optical properties.
Recently several reviews on methods of synthesis, water
solubilization and functionalization and applications of QDs
have been published.14,17,25,205–211 To become applicable to
Fig. 11 Schematic representation of some phase transfer strategies: (A) QDs capped with hydrophobic ligands; (B) QD ligands exchanged with water
soluble thiols; (C) QDs encapsulated with long chain polymers and chitin molecules with hydrophobic interaction; (D) QDs encapsulated with silica shells.
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biological systems certain biological molecules should be attached
to the surface of QDs without changing their properties. As
illustrated in the schematic representation in Fig. 14 such
biological molecules are attached to the surface of QDs via
cross linking hydrophobic surfactant molecules with reactive
functional groups. Various crosslinking molecules such
as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and
4-(N-maleimidomethyl)cyclohexane carboxylic acid N-hydroxyl
succinimide ester (SMCC) are commonly used which are attached
by adsorption, covalent linkage or electrostatic interaction. These
are few imitations from the enormous choice of phase transfer
strategies and functionalization of QDs.
To summarize, surface engineering is required to adjust
the fundamental properties of QDs, to make them stable and
soluble in different solvents and to create QD–biomolecule
hybrids which enhances the capability of participating in bio-
logical processes. However, depending on the type of QDs and
its respective biological application, the design of the surface of
QDs is based on its optical properties, stability, size, solubility,
biodegradability and biocompatibility. Attachments of bio-
molecules might lead to steric effects, alteration of enzymatic
activities or molecular recognition depending of the type of
biomolecules used for surface engineering of QDs. Hence, for
design of specific applications, modification and improvement
of bioconjugation and water-solubilization methods remain an
active area of research for bioimaging, detection and therapeutics.
A further area of research seeks to reduce QDs contact with normal
tissue and requires specific protein binding to tumor tissue.
Membrane proteins/receptors in living cells can be labeled either
directly with QD–antibody or QD–ligand conjugates.
The bioconjugated surface of QDs is able to adsorb, bind
and transport biomolecules such as drugs, probes and proteins.
Hence they have the potential to increase the sensitivity of imaging
at the cellular level including progression and treatment,212 cancer
detection,154 as radio-and chemo-sensitizing agents,213 as electron
and X-ray contrast agents and for targeted drug delivery.214
4. Biomedical applications of I–III–VI
QDs
In recent years, advances in nanotechnology, biology, chemistry,
physics and imaging has resulted in the emergence of theranostic
nanomedicines as capable agents for disease and patient-specific
diagnosis and treatment. A huge number of researches have been
published over the last decade and many of them have been
discussed in review articles.15,19,205,215,216 Herein we try to give an
informative overview about I–II–VI QDs in different biomedical
applications to provide a good starting point for interested
researchers.
Due to their broad range of absorption in the NIR region and
narrow emission, photophysical properties, large Stokes shift,
resistance to photobleaching, and higher QYs, I–III–VI QDs are
becoming more attractive for in vitro and in vivo targeting,
Fig. 12 (a) Overall synthetic scheme for the QD-loaded RGD-SOC micelles. (b) Synthetic scheme for RGD-modified N-succinyl-N0-octylchitosan
(SOC). (Reproduced from ref. 201 with permission from the American Chemical Society.)
Fig. 13 Schematic route for preparing DOX–FA–BSA(QMs). (Reproduced
from ref. 204 with permission from the Royal Society of Chemistry.)
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detection/imaging and therapy of cancer cells and tissues. More
specifically, functionalized I–III–VI QDs are now a component
of bioengineering for biosensors, imaging, drug delivery, PTT
and PDT applications. Selected biomedical applications are
explained in the following sections.
4.1 Biosensors
To screen the physiological activities of cells, that lead to a
range of intercellular diagnostics for diseases at the cellular
level, fluorescent-based biosensors have been implemented.
Among fluorescent-based biosensors, QDs display unique photo-
physical and photo-chemical properties relative to organic dyes
and protein fluorophores, and are thus superior fluorescence
probes in sensitive biosensor applications. The developments
of fluorescence and fluorescence resonance energy transfer
QD-based biosensors for the detection of biomolecules such
as sugars, nucleic acids, antibodies, antigens, enzymes, proteins,
pathogens, small molecules, cancer biomarkers and cancer cells
are widely explored.217,218 The advances of surface engineering
and bioconjugation in addition to unique properties such as
narrow emission bands, photostability against photobleaching,
single light source for simultaneous multi-colour excitation and
single-dot sensitivity of QDs means they are a viable alternative
choice for biological labelling. More specifically cadmium free
I–III–VI ternary QDs are of low cost, high stability, low toxicity
and high sensitivity, making them ideal candidates for bio-
sensor applications. Su et al.219 integrated fibrinogen with
fluorescent CIS QDs as a biosensing probe for selective and
sensitive detection of thrombin which is found in the blood
and causes blood clotting. Their study opens a great potential
for diagnosis of diseases related to coagulation abnormalities.
For clinical tests, diagnosis and other biomedical applications,
immunoassay is a valuable tool. The recent developments of
QD-based sensing immunoassay demonstrated multichannel
detection of toxins, drug residues, chemical residues, and
biomarkers. For example, Speranskaya et al.220 reported the
use of CIS/ZnS QDs as a fluorescent label for immunoassay
quantitative analysis of the mycotoxin aflatoxin B1. Their report
shows QD-based immunoassay displays enhanced sensitivity
compared to enzyme-based immunoassay. Recently, Kang,
Pan and their co-workers221 reported synthesis of a gram scale
polyethylenimine coated AIS QDs, and applied them for glucose
detection and luminescence properties of AIS QDs used in
optical imaging. The PL-intensity change of AIS QDs was used
to detect glucose to recognise peroxides. Koktysh and Weiss
et al.222 reported detection of biotin conjugated AIS/ZnS QDs
for reflectance and fluorescence measurements. Here the QDs
serve as a refractive index signal amplifier and as fluorescent
emitter. The other useful area of QDs application is QDs-based
detection of nucleic acids. For genetic target analysis on the
surface of QDs, DNA or RNA groups conjugated to form
fluorescent probes. After conjugation with QDs with DNA,
QDs with different emission colors can be applied to multi-
plexed detection of corresponding sequences that are immobi-
lized in a microarray platform.14 Organic fluorescent labels for
DNA detection have problems such as decomposition of DNA
and free radical formation due to photobleaching, and further the
interaction between DNA and proteins is disturbed. QDs avoid
Fig. 14 Schematic presentation of QDs bioconjugation using various methods of coupling reactions and interactions.
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such problems and permit color determination of orientations of
a single DNA molecule.223
Generally, QDs conjugated with numerous anticancer anti-
bodies can be applied for the detection of cancer biomarkers
in immuno-chromatographs and immune-microchannels.
For FRET-based detection, organic dye labelled strands, QDs
conjugated with oligonucleic acids are prevailing platforms.
QDs are greatly resistant to metabolic degradation and retain
fluorescence after modification. In addition, as compared to
cadmium based QDs, there is a real need to address the
applications of copper and silver based ternary QDs to continue
to explore better applications in live cells for the future.
Evaluation of the toxicity, monodisperse preparation and speci-
ficity of QDs remain a pressing issue for the broader community
interested in using QDs in live cells.
4.2 Optical imaging
Optical imaging is a fundamental tool that provides high
resolution in vitro and in vivo information for biological
researches. It has a number of advantages including low cost,
easy portability, and potential for multiple imaging. This allows
one to employ optical imaging techniques during surgery and
endoscopic processes. Optical imaging is advantageous for
imaging guided surgical resection of tumors and primary
detection of cancer cells. For both in vitro and in vivo purposes
cells or tissues can be labelled with QDs. Since copper/silver
based QDs have high QY, nontoxicity, aqueous dispersibility,
resistance to photobleaching, large surface area, long lumines-
cence life times and rich surface chemistry for targeted imaging
applications. I–III–VI QDs with these unique features can be
applied to fluorescent imaging, multicolor imaging and in
confocal imaging systems. Li et al.8 synthesized luminescent
CIS/ZnS QDs which were made water-dispersible through
ligand-exchange using DHLA and further used as a fluorescent
label for in vivo imaging in mice. Deng et al.224 synthesized NIR-
emitting AISe/ZnS QDs (with a QY of 40%) encapsulated with
poly(acrylic acid)-octylamine (PAA-based) amphiphilic polymer
micelles to make them water-soluble. The AISe/ZnS QDs func-
tioned as luminescent probes for in vitro and in vivo targeted
cell-imaging. For in vitro and in vivo studies RGD peptide
surface modification of polymer-wrapped AISe/ZnS QDs
enhanced the targeting capability of the tumor as a versatile
fluorescent probe. Wang et al.225 demonstrated surface modi-
fication of CIS/ZnS with trimethyl(tetradecyl)ammonium bromide
(TTAB) for in vitro labeling of HepG2, Hela and MCF-7 cells.
A fluorescence signal was observed in the cytoplasm and with
increasing time of incubation CIS/ZnS–TTAB can penetrate into
the nucleus. The small size of CIS/ZnS–TTAB particles of less
than 10 nm and the cationic surface charge introduced by TTAB
modification acted as main driving forces for the nuclear selectiv-
ity, CIS/ZnS–TTAB having ability to pass into the nucleus through
the nuclear pores. Zhao, Bai and co-workers170 reported that GSH
and MPA ligand exchange can provide CIS/ZnS QDs with a better
performance in solubility, stability and imaging breast tumor
cells. While fluorescence of CIS/ZnS – (GSH, MPA) QDs only stays
in the cytoplasm their QYs are better than for other capping
ligands such as 11-mercaptoundecanoic acid (MUA), cetyltrimethyl-
ammonium bromide (CTAB) and F127 under the same conditions.
Lee et al.226 employed folic acid receptor as a tumor targeting
ligand. The injected CIS/ZnS QDs were efficiently directed to the
tumor tissue and the fluorescence signal in the tumor is highest.
This means that CIS/ZnS QDs with folic acid receptor was success-
fully docked at the specific target. CISe/ZnS QDs conjugated with
tumor targeting peptides were found to lead to strong tumor-
targeting imaging probes.97
Up to now, there are only a handful of research articles
demonstrating CIS/ZnS, CISe/ZnS, AIS/ZnS and AISe/ZnS
QDs for effective use for in vitro and in vivo imaging
applications.227–229 Developments of technology and instru-
mentations related to different imaging modalities show there
is no perfect imaging method and all suffer from limitations.
Some of the limitations can be eradicated by advancements of
technology, but others are a function of basic biology and
chemistry, making it difficult to find a solution or even impos-
sible in some instances. Moreover, each modality delivers
information about the patient. In recent advances of QDs
technology, numerous research groups are developing multi-
functional or multimodal QDs that enable imaging more than a
single modality, enabling to exploit the advantages of each and
to obtain more information about the patient while reducing
the limiting factors.
4.3 Magnetic resonance imaging (MRI)
MRI is a widely used technique in the clinic for high resolution
imaging. MRI is regarded as one of leading diagnosis tools due
to its unique features including its benign impact to humans
and the environment since it is non-invasive with no exposure
to high energy radiation, low cost, and easy implementation,
high spatial resolution, and strong soft tissue contrast. Exploring
the above qualities, MRI is capable for precise diagnosis of
cancer. However, recently multiple modalities have been increas-
ingly adopted and simplified coupling the complimentary abilities
of different imaging modalities advanced. MRI images generally
can be classified into two different imaging modes – longitudinal
(T1)-weighed and transverse (T2) weighed images. MRI allows the
imaging in deep areas of the body which is not restricted by the
tissue. However, targeted contrast agents are required to achieve
molecular imaging, since the sensitivity is somewhat low.
Magnetic QDs have displayed great promise for targeted molecular
imaging using MRI techniques. Contrast agents can accelerate the
T1 and T2 relaxation rate in tumor cells and are used to increase
the contrast between normal and cancer cells. Positive contrast
agents are most particularly selected from paramagnetic metal
ions containing many unpaired electrons such as Mn2+, Gd3+ and
Fe3+.56,230–232 However, negative contrast agents generally employ
super-paramagnetic iron oxide nanoparticles such as Fe2O3 and
Fe3O4, due to biocompatibility.
233–235
In most MRI measurements magnetic QDs are used as con-
trast agents. However, to explore the advantages of absorption in
the biological window and fluorescent transitions, magnetic
metal doped I–III–VI type QDs are used. Researchers have already
developed combinations of magnetic nanoparticles and QDs for
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MRI. In work by Lin et al.236 CIS–Zn1xMnxS QDs were prepared
by doping Mn and used as an optical and T1 weighted MRI
contrast agent. The encapsulation of CTAB solution aids
magnetic QDs solubility in water. The results showed that
fluorescence of human pancreatic cancer cell line BXPC-3 was
observed clearly by confocal microscopy and were imaged by
MRI. Furthermore, the feasibility of Gd-labeled Fe3O4 and CIS
QDs conjugated with arginine-glycine-aspartic acid (RGD) was
investigated by Shen et al.237 Silica coating was then used to
modify the CuInS2 and Fe3O4 surface to achieve water disper-
sibility. Subsequently, the conjugation of Gd–diethylenetri-
aminepentaacetic acid (Gd–DTPA) and RGD peptides to the
modified QDs@SiO2 led to Fe3O4/CIS@SiO2 (Gd–DTPA)–RGD
nanoparticles. The ability of such multimodal probes for
in vitro and in vivo human pancreatic cancer BXPC-3 cells was
observed. The result showed that the fluorescence emission
from QDs was bright and a significant signal was also detected
in MRI targeted T1 and T2 signals, leading to enhanced effects
for the treatment of cancer cells. Ding et al.238 synthesized
PEGylated CIS@ZnS:Mn QDs which were applied for in vivo
fluorescence and MR imaging. Biodistribution of injected QDs
in the mouse main organs such as heart, liver, spleen, kidney was
observed, with the liver presenting the strongest fluorescence,
reflecting that the liver functions to clean the blood of foreign
objects and harmful substances.
Most recently, our group reported amphiphilic poly(maleic
anhydridealt-1-octadecene) stabilized gadolinium (Gd) based
CIS/ZnS QDs modified with carbodiimide chemistry for a dual-
modality nanoprobe magnetic resonance and optical imaging.
This material was also used for specific targeting via a folate
receptor mediated targeted receptor.239
4.4 Drug delivery
The surface chemistry of QDs enables connection of numerous
ligands for different functionalities and loading of both hydro-
phobic and hydrophilic therapeutics. Moreover, their physical
and chemical stabilities can lead to long systemic circulation
times in the cell. With the utility of various coupling strategies,
the QDs can be functionalized by a range of cancer-targeting
moieties (e.g. aptamers, anti-cancer drugs and folic acids).
QD-based drug delivery paths must be capable to carry and
release the drug to a specific location. Drug delivery systems
may be covalent or noncovalent systems and require specific
control of temperature, pH, and biological reactions. Covalent
systems involve a covalent linkage between the drug and QD
which requires breaking of the bond between the QD and the
drug which may restrict the release of the drug. Careful design
of this linker can give cleavage under specific conditions
(thermal, enzymatic or pH based). Noncovalent drug delivery
is any form of drug carrier that does not form a chemical bond,
i.e. the QDs may encapsulate the drug or form stabilizing
pockets. Extensive reports have been made about drug delivery
systems using QDs.204,214,240,241
Previously our group reported AIS/ZnS QDs, by conjugating with
anticancer drug methotrexate, that possesses dual-functionality,
for optical imaging and drug delivery.242 The anticancer drug
covalently bonded on the surface of QDs which were effective
carriers for the anticancer drug.
4.5 Photo-therapeutic applications
Biological researches has also relied on developing alternative
cancer cell treatment modalities that are safe, powerful and
cost effective. Near infrared (NIR) light mediated photo-
therapeutic methods with QDs, such as PTT and PDT show
great advantages including better spatiotemporal selectivity,
avoidance of surgery, noninvasive, effective and fast treatment,
lower cost and reduced side effects.
PTT is a therapeutic strategy, which involves the NIR photo-
absorbers generating hyperthermia for thermal ablation of
cancer cells on exposure to NIR laser irradiation. It can eradi-
cate the cancer cell in primary tumors and can be combined
with other therapeutic modalities to treat cancer cells.243,244
Up to now, numerous types of photothermal therapeutics
have been adopted including plasmonic nanoparticles,243,245
transition metal sulfide/oxides,246–249 organic nanoagents,250–252
nanocarbons253 and QDs.254 On the other hand, PDT involves a
photosensitizer which can change triplet oxygen (3O2) molecule to
reactive oxygen species (such as singlet oxygen, hydroxyl radical,
peroxides) on exposure to single wavelength light, which causes
the death of nearby malignant cancer cells. A more detailed
discussion of PDT is provided in a review reported by Lucky
et al.255 Wu et al.254 synthesized CIS/ZnS QDs and used them for
PTT and PDT by conjugating with reduced graphene oxide
nanosheets and linking by liposomes, which improves the medical
therapeutics of these toxic element free I–III–VI band QDs. Ghosh
et al.256 synthesized CuFeS2 QDs by substituting the conventional
In atom and applied them for PTT. The report shows that Fe can
create an intermediate band which is suitable for light-to-heat
conversion.
Recently, Lv et al.257 demonstrated the in vitro and in vivo
theranostic applications of CIS/ZnS which combines imaging
and therapeutic nanomedicines. Such ‘‘all in one’’ nanomedicines
are attractive for particular diagnosis and effective destruction of
tumors. Simultaneous PTT and PDT using single wavelength laser
irradiation (Fig. 15) leads to application of these materials for
effective synergistic phototherapy against tumors with negligible
toxicity.
5. Toxicity and biocompatibility
Biocompatibility of QDs is related to the response of the
immune system following its administration and intrinsic toxicity
due to biodegradation metabolites. In general, most QDs are
prepared in organic solvents, and a phase change, surface
functionalization and bioconjugation is usually required before
applying them for biomedical uses. The cytotoxicity issue is to
some degree challenging. The level of toxicity would relate to the
intrinsic toxic nature of QDs themselves, size and structure
effects, surface modification, solubility, stability of ligands,
charge, delivery method and dosage injected, biodegradability,
biodistribution, and pharmacokinetics, and should be carefully
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considered. Furthermore, QDs must be eliminated from the
body in the shortest possible time. Despite all the inspiring
progress of QDs, the cytotoxic actions are not entirely clear, since
in vitro and animal studies are conducted with varied range of
QDs concentration, size and structure, surface modifications,
exposure time, and delivery methods, etc. making it challenging to
forecast the cytotoxicity of QDs for new designs.56,167,214,227,232,239
However, compared to cadmium based QDs, I–III–VI QDs have
lower cytotoxicity. Furthermore, their higher PLQY, size tunable
photoluminescence, high photo and chemical stability and broad
absorption spectra are a further advantage. Wider research should
be addressed to eliminate cytotoxicity related issues.
Clearance of QDs from the body is a key factor for clinical
application of any in vivo diagnosis and therapeutic agents.
It was previously reported that smaller QDs (o5 nm) can be
removed by renal pathways from the blood which protects QDs
accumulation on the cancer cells. QDs of 10–20 nm size can be
consumed by the liver, and larger QDs (4200 nm) size are
filtered by spleen or reticulo-endothelial system.258–260 Once
the QDs are transported to the cancer cell, they should be
spread to the cancer cell, consumed by the cancer cell, and
localized intracellularly to execute therapeutic action. Pons
et al.73 reported that shell growth and monitored dosage of
CIS/ZnS QDs much reduced in vivo local acute toxicity. To
evaluate the in vivo clearance process and biodistribution, adult
zebrafish were exposed to a solution of as-prepared Q-dots.
For example, Chetty et al.261 studied zebrafish embryos to check
the toxicities of CIS/ZnS QDs. As reported up to a minimal
dosage it shows minimal toxicity and minimal acute terato-
genic consequences. In summary, there is still much work to do
Fig. 15 In vivo thermal imaging and PTT. (A) Thermal IR imaging of 4T1 tumor-bearing mice after i.v. injection of ZCIS NMs-25 and exposure to 660 nm
laser irradiation. (B) Temperature change curves of 4T1 tumors in mice treated with or without ZCIS NMs-25 and laser irradiation as a function of
irradiation time. (C) Growth curves of tumors in mice from the different treatment groups. Tumor volumes were normalized to their initial sizes. Error bars
represent the standard deviations of three mice per group. (D) Body weight curves of mice in the different treatment groups. (E) Digital photos and
(F) H&E staining of tumor tissues collected from mice in the different groups at the end of treatment. (G) H&E-stained slices of the heart, liver, spleen,
lung, and kidney in mice without and with PTT treatment. Scale bar = 50 mm. (Reproduced from ref. 257 with permission from the American Chemical
Society.)
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in understanding toxicity concerns in the application of QDs in
bioapplications. Study of experimental conditions, dosages,
experimental cell lines for in vitro studies, and animal models
for in vivo studies should lead to increasing understanding of
toxicity. In vitro experiments are valuable to investigate new
QDs at the early stages of research for quantitative measure-
ments of toxicity. Whereas, in vivo experiments can be used to
evaluate neurological, cardiovascular, immunological, repro-
ductive and developmental related toxicity to assess chronic
systemic toxicity of QDs.
6. Conclusions and outlook
Bioconjugated QDs are widely used as nanoplatforms for
several biomedical applications, such as biosensing, imaging,
diagnosis and therapy. Specifically, through careful material
composition and engineering with versatile surface molecules
for biological conjugation can lead to very advantageous and
multifunctional I–III–VI QD-based materials for advanced
theranostics. In this review, we discussed recent advances of
I–III–VI QDs for various biological applications. QD-based
nanoprobes are considered as effective for biosensors, optical
imaging, MRI, drug carriers, in therapy and in multimodal
nanomedicines. We have discussed the optical properties,
synthesis protocols, and surface modification strategies as
well as bioconjugation of I–III–VI QDs. The optical properties
of I–III–VI QDs display excellent features that are essential for
biosensors, imaging, PTT and PDT. For example, tunable
photoluminescence, a broad absorption spectra spanning
from UV to NIR, higher QY and large Stokes shift are observed.
In addition, the availability of various surface chemistries
and low toxicity of such QDs leads to novel biomedical
applications.
Despite extensive reports of the synthesis of doped ternary
systems both in core and shell, the proportion and location
of the incoming atom should be carefully considered for
novel synthesis methods. Other challenges to be addressed
for QD probes are their biocompatibility, targeting efficacy,
noninvasiveness and long-term stability, and clinical applications.
Pointing to expanding QDs usage even further, early steps
have been made to design multifunctional nanomedicines,
that promise to combine the advantages of multiple imaging
modalities, such as contrast agent together with chemotherapy
and phototherapy. Prior to biological application with these
I–III–VI QDs, we should reduce the toxicity of these materials by
using appropriate surface modification such as biocompatible
polymers, DNA/RNA, peptides etc. After improving their bio-
compatibility, in future, research development could focus on
the QD-based biomedical imaging, and therapeutic interven-
tion techniques for monitoring and therapy of malignant cells.
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